However, the HER-2/neu status is mainly used for identifying patients with advanced breast cancer who may benefit from the therapy with anti-HER-2 antibody trastuzumab/Herceptin® (Genetech, San Francisco, CA) a humanized murine monoclonal antibody which has been shown to be effective in prolonging survival in patients with receptor positive metastatic breast carcinoma [19]. The gene discussed is ERBB2; the disease is breast carcinoma.